MYOK MyoKardia Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * GIANAKAKOS ANASTASIOS	2. Issuer Name and Ticker or Trading Symbol MyoKardia, Inc. [ MYOK ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President and CEO
(Last)          (First)          (Middle) C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY	3. Date of Earliest Transaction (MM/DD/YYYY) 5/11/2020
(Street) BRISBANE, CA 94005 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	5/11/2020		S(1)		600	D	$98.6883 (2)	63522 (3)	D
Common Stock	5/11/2020		S(1)		1700	D	$100.5056 (4)	61822	D
Common Stock	5/11/2020		S(1)		18581	D	$101.9044 (5)	43241	D
Common Stock	5/11/2020		S(1)		3519	D	$102.5635 (6)	39722	D
Common Stock	5/11/2020		S(1)		600	D	$103.33 (7)	39122	D
Common Stock								129407	I	By Reporting Person's Trust 2 (8)
Common Stock								300000	I	By Reporting Person's Trust 4
Common Stock								7000 (9)	I	By Reporting Person's Trust 5
Common Stock								10000 (10)	I	By Reporting Person's Trust 6
Common Stock								53087	I	By Trust 1
Common Stock								53087	I	By Trust 2
Common Stock								53087	I	By Trust 3

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(2)	Represents the weighted average sale price of the shares sold ranging from $98.50 to $99.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in this footnote and footnotes 4 through 7.
(3)	Excludes 10,000 shares previously owned directly which were contributed on May 6, 2020 to the MJA Legacy Trust, of which the Reporting Person's children are beneficiaries.
(4)	Represents the weighted average price of the shares sold ranging from $100.01 to $100.94 per share.
(5)	Represents the weighted average price of the shares sold ranging from $101.07 to $102.05 per share.
(6)	Represents the weighted average price of the shares sold ranging from $102.11 to $103.09 per share.
(7)	Represents the weighted average price of the shares sold ranging from $103.19 to $103.54 per share.
(8)	Excludes 1,000 shares previously held by The TKG Trust dated November 2, 2006 which were redistributed back to the Reporting Person directly and immediately transferred to The TKG 2020 Irrevocable Trust on May 5, 2020.
(9)	Includes 1,000 shares previously held by The TKG Trust dated November 2, 2006 which were redistributed back to the Reporting Person directly and immediately transferred to The TKG 2020 Irrevocable Trust on May 5, 2020.
(10)	Includes 10,000 shares previously owned directly which were contributed on May 6, 2020 to the MJA Legacy Trust, of which the Reporting Person's children are beneficiaries.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
GIANAKAKOS ANASTASIOS C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE, CA 94005	X		President and CEO

Signatures
/s/ Cynthia Ladd, as Attorney-in-Fact		5/13/2020
**Signature of Reporting Person		Date